Income Statement
BRIACELL THERAPEUTICS CORP.
BCTX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Jul 31, 2025 2025 FY | Jul 31, 2024 2024 FY | Jul 31, 2023 2023 FY | Jul 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
27.20 | 33.33 | 23.27 | 15.29 |
|
Research & Development
|
21.27 | 27.18 | 15.34 | 8.02 |
|
Selling, General & Administrative
|
5.93 | 6.15 | 7.94 | 7.27 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-27.20 | -33.33 | -23.27 | -15.29 |
|
Non-Operating Income
|
0.11 | 0.26 | 2.97 | -11.55 |
|
Interest Income
|
0.12 | 0.29 | 0.89 | 0.14 |
|
Interest Expense
|
- | - | - | 0.00 |
|
Other Non-Op Income / Expense
|
-0.22 | -0.11 | - | - |
|
Income Before Tax
|
26.56 | 4.93 | -20.30 | -26.84 |
|
Income Tax Expense
|
- | - | - | - |
|
Non-Controlling Interest
|
-0.24 | -0.14 | - | - |
|
Net Income
|
-26.31 | -4.79 | -20.30 | -26.84 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Jul 31, 2025 2025 FY | Jul 31, 2024 2024 FY | Jul 31, 2023 2023 FY | Jul 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-27.20 | -33.33 | -23.27 | -15.27 |
|
Earnings Per Share (Basic)
|
-62.19 | -0.29 | -1.30 | -1.73 |
|
Diluted EPS
|
-62.19 | -0.29 | -1.30 | - |
|
Weighted Average Shares
|
0.42 | 16.45 | 15.62 | 15.49 |
|
Diluted Weighted Avg Shares
|
0.42 | 16.45 | 15.62 | - |
|
Comprehensive Income
|
- | - | - | - |